GT Biopharma (NASDAQ:GTBP) Posts Earnings Results, Misses Estimates By $0.45 EPS

GT Biopharma (NASDAQ:GTBP) released its quarterly earnings results on Friday. The company reported ($0.83) earnings per share for the quarter, missing the consensus estimate of ($0.38) by ($0.45), FiscalAI reports.

GT Biopharma Price Performance

GTBP stock traded up $0.19 during trading on Friday, reaching $0.92. 12,937,039 shares of the company were exchanged, compared to its average volume of 528,092. The company has a 50-day moving average of $0.72 and a two-hundred day moving average of $1.70. The company has a market capitalization of $3.27 million, a price-to-earnings ratio of -0.23 and a beta of 1.38. GT Biopharma has a twelve month low of $0.54 and a twelve month high of $4.10.

Analyst Ratings Changes

A number of brokerages have recently issued reports on GTBP. Weiss Ratings reissued a “sell (e+)” rating on shares of GT Biopharma in a research report on Wednesday, October 8th. Wall Street Zen cut shares of GT Biopharma from a “hold” rating to a “sell” rating in a report on Saturday, September 20th. One research analyst has rated the stock with a Strong Buy rating, one has assigned a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $11.00.

About GT Biopharma

GT Biopharma, Inc, a clinical stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology products based on its proprietary Tri-specific Killer Engager (TriKE) fusion protein immune cell engager technology platform. It develops GTB-3550, a single-chain tri-specific recombinant fusion protein conjugate that is in Phase I clinical trial for the treatment of myelodysplastic syndromes, refractory/relapsed acute myeloid leukemia or advanced systemic mastocytosis, and CD33+ malignancies.